{"disease":{"id":"endometrial-endometrioid-adenocarcinoma","name":"endometrial endometrioid adenocarcinoma"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT04291612","title":"Observational Study of Women With Endometrial Cancer Who Receive the Standard Treatment for Their Disease","phase":"","overall_status":"RECRUITING","enrollment_count":1715,"lead_sponsor_name":"Memorial Sloan Kettering Cancer Center","has_results":false},{"nct_id":"NCT02834013","title":"Nivolumab and Ipilimumab in Treating Patients With Rare Tumors","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":818,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT03914612","title":"Testing the Addition of the Immunotherapy Drug Pembrolizumab to the Usual Chemotherapy Treatment (Paclitaxel and Carboplatin) in Stage III-IV or Recurrent Endometrial Cancer","phase":"PHASE3","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":813,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":true},{"nct_id":"NCT04604613","title":"Prediction of Recurrence Among Low Risk Endometrial Cancer Patients","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":518,"lead_sponsor_name":"M.D. Anderson Cancer Center","has_results":false},{"nct_id":"NCT05256225","title":"Testing the Addition of Herceptin Hylecta or Phesgo to the Usual Chemotherapy for HER2 Positive Endometrial Serous Carcinoma or Carcinosarcoma","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":360,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT03660826","title":"Testing the Combination of Olaparib and Durvalumab, Cediranib and Durvalumab, Olaparib and Capivasertib, and Cediranib Alone in Recurrent or Refractory Endometrial Cancer Following the Earlier Phase of the Study That Tested Olaparib and Cediranib in Comparison to Cediranib Alone, and Olaparib Alone","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":288,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":true},{"nct_id":"NCT01010126","title":"Temsirolimus and Bevacizumab in Treating Patients With Advanced Endometrial, Ovarian, Liver, Carcinoid, or Islet Cell Cancer","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":252,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":true},{"nct_id":"NCT06689956","title":"Outcomes of Low-Risk Endometrial Cancer With Isolated Tumor Cells in the Sentinel Lymph Nodes: A Prospective, Multicenter, Single-Arm Observational Study","phase":"","overall_status":"RECRUITING","enrollment_count":212,"lead_sponsor_name":"Mayo Clinic","has_results":false},{"nct_id":"NCT03422198","title":"Short Course Vaginal Cuff Brachytherapy in Treating Participants With Stage I-II Endometrial Cancer","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":188,"lead_sponsor_name":"University of Utah","has_results":true},{"nct_id":"NCT00492778","title":"Radiation Therapy With or Without Cisplatin in Treating Patients With Recurrent Endometrial Cancer","phase":"PHASE2","overall_status":"UNKNOWN","enrollment_count":165,"lead_sponsor_name":"GOG Foundation","has_results":true},{"nct_id":"NCT04214067","title":"Testing the Addition of the Immunotherapy Drug, Pembrolizumab, to the Usual Radiation Treatment for Newly Diagnosed Early Stage High Intermediate Risk Endometrial Cancer","phase":"PHASE3","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":164,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT07436793","title":"Progestins for the Treatment of Endometrial Cancer or Precancers of the Uterus Before Surgery, The Pro-Window Trial","phase":"PHASE2","overall_status":"NOT_YET_RECRUITING","enrollment_count":140,"lead_sponsor_name":"New Mexico Cancer Research Alliance","has_results":false},{"nct_id":"NCT03748186","title":"Study of STRO-002, an Anti-Folate Receptor Alpha (FolRα) Antibody Drug Conjugate in Ovarian & Endometrial Cancers","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":136,"lead_sponsor_name":"Sutro Biopharma, Inc.","has_results":false},{"nct_id":"NCT01935934","title":"Cabozantinib S-Malate in Treating Patients With Recurrent or Metastatic Endometrial Cancer","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":102,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":true},{"nct_id":"NCT02397083","title":"Levonorgestrel-Releasing Intrauterine System With or Without Everolimus in Treating Patients With Atypical Hyperplasia or Stage IA Grade 1 Endometrial Cancer","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":102,"lead_sponsor_name":"M.D. Anderson Cancer Center","has_results":false},{"nct_id":"NCT04972682","title":"[SENTRY] Tailoring Postoperative Management Through Sentinel Lymph Node Biopsy in Low- and Intermediate-Risk Endometrial Cancer","phase":"NA","overall_status":"COMPLETED","enrollment_count":102,"lead_sponsor_name":"Moscow City Oncology Hospital No. 62","has_results":false},{"nct_id":"NCT01737619","title":"PET/CT and Lymph Node Mapping in Finding Lymph Node Metastasis in Patients With High-Risk Endometrial Cancer","phase":"NA","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":101,"lead_sponsor_name":"M.D. Anderson Cancer Center","has_results":true},{"nct_id":"NCT07062016","title":"Molecular and ctDNA Characterization of High-Risk Endometrial Cancer","phase":"","overall_status":"RECRUITING","enrollment_count":100,"lead_sponsor_name":"Mayo Clinic","has_results":false},{"nct_id":"NCT05538897","title":"Testing the Addition of the AKT Inhibitor, Ipatasertib, to Treatment With the Hormonal Agent Megestrol Acetate for Recurrent or Metastatic Endometrial Cancers","phase":"PHASE1, PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":96,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT03008408","title":"A Phase II, Two-Arm Study of Everolimus and Letrozole, +/- Ribociclib (Lee011) in Patients With Advanced or Recurrent Endometrial Carcinoma","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":90,"lead_sponsor_name":"M.D. Anderson Cancer Center","has_results":false},{"nct_id":"NCT05112601","title":"Testing Nivolumab With or Without Ipilimumab in Deficient Mismatch Repair System (dMMR) Recurrent Endometrial Carcinoma","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":81,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT06213571","title":"Remote Home-Based Exercise Program for Strength Training in Endometrial Cancer Survivors in Rural Areas","phase":"NA","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":80,"lead_sponsor_name":"Mayo Clinic","has_results":false},{"nct_id":"NCT05231122","title":"Pembrolizumab Combined With Bevacizumab With or Without Agonist Anti-CD40 CDX-1140 for the Treatment of Patients With Recurrent Ovarian Cancer","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":80,"lead_sponsor_name":"Roswell Park Cancer Institute","has_results":false},{"nct_id":"NCT05001282","title":"A Study to Evaluate ELU001 in Patients With Solid Tumors That Overexpress Folate Receptor Alpha (FRα)","phase":"PHASE1, PHASE2","overall_status":"TERMINATED","enrollment_count":79,"lead_sponsor_name":"Elucida Oncology","has_results":false},{"nct_id":"NCT03348631","title":"Tazemetostat in Treating Patients With Recurrent Ovarian or Endometrial Cancer","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":62,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":true},{"nct_id":"NCT05950464","title":"Testing Different Amounts of the Combination of Drugs M1774 and ZEN-3694 for the Treatment of Recurrent Ovarian and Endometrial Cancer","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":60,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT05542407","title":"ONC201 and Atezolizumab in Obesity-Driven Endometrial Cancer","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":58,"lead_sponsor_name":"UNC Lineberger Comprehensive Cancer Center","has_results":false},{"nct_id":"NCT07349641","title":"A Study of Weight Loss Intervention With Tirzepatide and Progestin Intrauterine Device to Treat Endometrial Hyperplasia and Grade 1 Endometrial Cancer","phase":"PHASE2","overall_status":"NOT_YET_RECRUITING","enrollment_count":55,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT04092270","title":"A Study Combining the Peposertib (M3814) Pill With Standard Chemotherapy in Patients With Ovarian Cancer With an Expansion in High Grade Serous Ovarian Cancer and Low Grade Serous Ovarian Cancer","phase":"PHASE1","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":54,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT03018249","title":"Medroxyprogesterone Acetate With or Without Entinostat Before Surgery in Treating Patients With Endometrioid Endometrial Cancer","phase":"EARLY_PHASE1","overall_status":"COMPLETED","enrollment_count":50,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":true},{"nct_id":"NCT02142803","title":"TORC1/2 Inhibitor MLN0128 and Bevacizumab in Treating Patients With Recurrent Glioblastoma or Advanced Solid Tumors","phase":"PHASE1","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":50,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":true},{"nct_id":"NCT02684227","title":"Enzalutamide, Carboplatin, and Paclitaxel in Treating Patients With Stage III-IV or Recurrent Endometrioid Endometrial Cancer","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":50,"lead_sponsor_name":"M.D. Anderson Cancer Center","has_results":true},{"nct_id":"NCT02020707","title":"Nab-Paclitaxel and Bevacizumab in Treating Patients With Unresectable Stage IV Melanoma or Gynecological Cancers","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":43,"lead_sponsor_name":"Mayo Clinic","has_results":false},{"nct_id":"NCT03300557","title":"Exemestane in Treating Patients With Complex Atypical Hyperplasia of the Endometrium/Endometrial Intraepithelial Neoplasia or Low Grade Endometrial Cancer","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":40,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":true},{"nct_id":"NCT01210222","title":"Trebananib in Treating Patients With Persistent or Recurrent Endometrial Cancer","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":35,"lead_sponsor_name":"Gynecologic Oncology Group","has_results":true},{"nct_id":"NCT00478426","title":"Sunitinib Malate in Treating Patients With Recurrent or Metastatic Endometrial Cancer","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":34,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":true},{"nct_id":"NCT03120624","title":"VSV-hIFNbeta-NIS With or Without Ruxolitinib Phosphate in Treating Stage IV or Recurrent Endometrial Cancer","phase":"PHASE1","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":34,"lead_sponsor_name":"Mayo Clinic","has_results":true},{"nct_id":"NCT05498597","title":"AMT-151 in Patients With Selected Advanced Solid Tumours","phase":"PHASE1","overall_status":"UNKNOWN","enrollment_count":30,"lead_sponsor_name":"Multitude Therapeutics Inc.","has_results":false},{"nct_id":"NCT04049227","title":"Abemaciclib and Letrozole in Treating Patients With Endometrial Cancer","phase":"EARLY_PHASE1","overall_status":"COMPLETED","enrollment_count":27,"lead_sponsor_name":"Northwestern University","has_results":false},{"nct_id":"NCT01440998","title":"Dasatinib, Paclitaxel, and Carboplatin in Treating Patients With Stage III-IV or Recurrent Endometrial Cancer","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":18,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT04719273","title":"Onapristone and Anastrozole for the Treatment of Refractory Hormone Receptor Positive Endometrial Cancer","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":14,"lead_sponsor_name":"Thomas Jefferson University","has_results":false},{"nct_id":"NCT02728258","title":"Copanlisib in Treating Patients With Persistent or Recurrent Endometrial Cancer","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":11,"lead_sponsor_name":"NRG Oncology","has_results":true},{"nct_id":"NCT06278857","title":"SATELLITE Study (feaSibility sAfeTy Efficacy dostarLimab earLy-stage defIcient endomeTrial cancEr)","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":10,"lead_sponsor_name":"Queensland Centre for Gynaecological Cancer","has_results":false},{"nct_id":"NCT03677024","title":"Evaluation of the Efficacy for Sentinel Lymph Node Policy in Intermediate-risk Endometrial Carcinomas","phase":"NA","overall_status":"WITHDRAWN","enrollment_count":0,"lead_sponsor_name":"Fudan University","has_results":false},{"nct_id":"NCT07226102","title":"Virtual Mental Health Intervention to Address Fear of Progression for Women With High Risk or Stage III-IV Gynecologic or Breast Cancer","phase":"NA","overall_status":"WITHDRAWN","enrollment_count":0,"lead_sponsor_name":"City of Hope Medical Center","has_results":false},{"nct_id":"NCT05390021","title":"PET/MRI in Endometrial Cancer","phase":"NA","overall_status":"WITHDRAWN","enrollment_count":0,"lead_sponsor_name":"Massachusetts General Hospital","has_results":false}],"total":46},"guidelines":[],"source":"Drug Landscape verified database"}